10-Q: Altimmune Q2 Loss Narrows, MASH Trial Shows Strong Resolution

Altimmune, Inc. reported a narrower net loss in Q2 2025, driven by reduced R&D expenses, while its lead MASH drug, pemvidutide, demonstrated significant resolution rates in its Phase 2b trial.

Summary

• Net loss for the three months ended June 30, 2025, decreased by 10% to $22.1 million from $24.6 million in the same period of 2024.
• Net loss for the six months ended June 30, 2025, decreased by 15% to $41.7 million from $49.0 million in the same period of 2024.
• Research and development expenses decreased by 19% in Q2 2025 and 22% for the six months, primarily due to reduced MASH trial enrollment costs and the termination of the HepTcell program.
• Topline results from the IMPACT Phase 2b trial for MASH showed 59.1% and 52.1% MASH resolution rates for pemvidutide 1.2 mg and 1.8 mg doses, respectively, compared to 19.1% for placebo (p<0.0001).
• Pemvidutide achieved mean weight loss of 5.0% (1.2 mg) and 6.2% (1.8 mg) at 24 weeks, versus 1.0% in the placebo arm (p<0.001).
• The company initiated Phase 2 trials for pemvidutide in Alcohol Use Disorder (RECLAIM) and Alcohol-Associated Liver Disease (RESTORE).
• Cash, cash equivalents, and restricted cash increased significantly to $183.1 million as of June 30, 2025, from $36.9 million at December 31, 2024.
• Secured a $100.0 million term loan facility with Hercules Capital, Inc., drawing $15.0 million in the first tranche.
• Raised $72.3 million in net proceeds from at-the-market (ATM) offerings during the first six months of 2025, with $106.2 million remaining available under the 2025 ATM program as of June 30, 2025.

Sentiment

Score: 8

Explanation: The company reported a narrower net loss and significantly increased its cash position through successful financing activities. Most importantly, the topline results from the Phase 2b MASH trial for pemvidutide demonstrated strong efficacy in MASH resolution and favorable safety, which are highly positive indicators for its lead therapeutic candidate. While fibrosis improvement was not statistically significant in the primary ITT analysis, supplemental AI-based analysis showed significant reduction, and new litigation is a concern, the overall clinical data and financial stability present a very positive outlook.

Positives

• Significant MASH resolution rates (59.1% and 52.1%) in the IMPACT Phase 2b trial for pemvidutide, statistically superior to placebo (19.1%).
• Pemvidutide demonstrated strong anti-fibrotic activity, including a 30.6% reduction in fibrosis by 60% or more in the 1.8 mg group (AI-based analysis) and statistically significant changes in non-invasive fibrosis tests (ELF, VCTE).
• Favorable safety and tolerability profile for pemvidutide in the MASH trial, with low discontinuation rates (0.0% and 1.2% for pemvidutide vs 2.4% for placebo) and no serious adverse events related to study medication.
• Achieved clinically meaningful weight loss (5.0% and 6.2%) with pemvidutide in MASH patients.
• Net loss decreased by 10% in Q2 2025 and 15% for the six months ended June 30, 2025, compared to the prior year periods.
• Cash and cash equivalents increased substantially to $183.1 million, providing liquidity for at least the next 12 months.
• Successful capital raise through a new $100.0 million term loan and ongoing at-the-market equity offerings.
• Shareholder derivative litigation filed in June 2024 was dismissed without prejudice in February 2025.

Negatives

• Fibrosis improvement without worsening of MASH was not statistically significant in the primary intent-to-treat (ITT) analysis (31.8% and 34.5% for pemvidutide vs 25.9% for placebo).
• Interest income decreased by 48% in Q2 2025 and 42% for the six months ended June 30, 2025, due to lower returns on cash equivalents and short-term investments.
• Increased interest expense by $0.3 million in both Q2 and the six months ended June 30, 2025, due to the new term loan.
• Net cash used in operating activities increased to $36.2 million for the six months ended June 30, 2025, from $34.5 million in the prior year.
• Accumulated deficit increased to $603.1 million as of June 30, 2025.
• The company has not generated any revenues from product sales to date and acknowledges the need for additional capital for long-term needs.
• A new class action complaint was filed on August 5, 2025, alleging false and misleading statements related to pemvidutide and the IMPACT trial.

Risks

• The company has not generated any revenues from product sales to date and there is no assurance of any future revenues from product sales.
• The company has incurred significant losses since inception and has not generated positive cash flows from operations, requiring reliance on debt and equity financing.
• Future capital needs, including for planned clinical trials, may require additional equity or debt financing, or monetization of existing programs through partnerships or sales to third parties.
• The Term Loan is secured by substantially all of the company's assets, and an event of default could lead to acceleration of obligations and foreclosure on collateral.
• Global economic uncertainties, including tariffs and counter-tariffs, could negatively impact operations through inflationary pressures, supply chain disruptions, and volatility in capital markets, foreign exchange rates, and interest rates.
• Ongoing litigation, such as the class action complaint filed on August 5, 2025, could be costly, impose a significant burden on management, and have an adverse impact regardless of the outcome.
• The results of any current or future litigation cannot be predicted with certainty.

Future Outlook

The company believes its current cash on hand as of June 30, 2025, combined with expected R&D incentives, is sufficient to fund operations for at least a twelve-month period from the issuance date of the financial statements. However, for long-term capital needs, including planned clinical trials, the company must actively pursue additional equity or debt financing, or monetize existing programs through partnerships or sales to third parties. The company is assessing the impact of the recently enacted One Big Beautiful Bill Act (OBBBA) but does not expect it to materially impact its estimated annual effective tax rate in 2025.

Management Comments

• We intend to defend vigorously against this litigation.

Industry Context

Altimmune operates in the highly competitive biopharmaceutical sector, specifically targeting liver and cardiometabolic diseases with its GLP-1/glucagon dual receptor agonist, pemvidutide. This class of drugs is a rapidly evolving and high-interest area, with significant market potential in conditions like MASH and obesity. The company's expansion into Alcohol Use Disorder (AUD) and Alcohol-Associated Liver Disease (ALD) indications for pemvidutide positions it to address broader unmet medical needs within the liver disease space, diversifying its pipeline beyond MASH.

Comparison to Industry Standards

• The MASH resolution rates of 59.1% (1.2 mg) and 52.1% (1.8 mg) for pemvidutide are competitive within the MASH therapeutic landscape. For comparison, Madrigal Pharmaceuticals' resmetirom, an oral THR-beta agonist, achieved MASH resolution without worsening of fibrosis in 25.9% to 29.9% of patients in its Phase 3 MAESTRO-NASH trial, leading to its FDA approval. While direct cross-trial comparisons are challenging due to differences in patient populations, trial design, and endpoints, Altimmune's reported rates appear favorable.
• The weight loss observed with pemvidutide (5.0% to 6.2%) is also a notable benefit, aligning with the growing trend of GLP-1 based therapies offering metabolic improvements. This is generally lower than the weight loss seen with leading GLP-1/GIP agonists like Eli Lilly's Zepbound (tirzepatide), which showed average weight reductions of 15-20% in obesity trials, or Novo Nordisk's Wegovy (semaglutide) at 15%. However, pemvidutide's primary focus is MASH resolution, where weight loss is a secondary but beneficial outcome, and its dual GLP-1/glucagon mechanism may offer differentiated benefits for liver health beyond pure weight reduction.
• The anti-fibrotic activity, particularly the 30.6% of subjects achieving a 60% or more reduction in fibrosis (AI-based analysis), is a critical differentiator for MASH, as fibrosis reversal is a key goal. This level of fibrosis improvement is a strong indicator of therapeutic potential in a disease with high unmet need.

Legal Proceedings

• A shareholder derivative complaint (In re Altimmune, Inc. Stockholder Derivative Litigation) filed on June 4, 2024, alleging false and misleading statements and breaches of fiduciary duty, was dismissed without prejudice on February 3, 2025.
• A new class action complaint (Collier v. Altimmune, Inc.) was filed on August 5, 2025, alleging violations of the Securities Exchange Act of 1934 by making false and misleading statements and omissions of material fact between August 10, 2023, and June 25, 2025, related to pemvidutide and the IMPACT Phase 2b trial in MASH. The company intends to defend vigorously.

Stakeholder Impact

• Shareholders: Positive impact from strong MASH trial results and improved liquidity, but potential dilution from ongoing ATM offerings and uncertainty from new class action litigation.
• Patients (MASH, AUD, ALD, Obesity): Potential for a new, effective treatment option (pemvidutide) for significant unmet medical needs.
• Employees: Continued employment and potential for growth as clinical programs advance.
• Creditors (Hercules Capital): Secured loan provides a stable return, but repayment depends on company's future success and ability to raise further capital.

Next Steps

• Continue to pursue additional indications for pemvidutide that leverage its differentiated clinical profile.
• Continue enrollment and conduct of the RECLAIM Phase 2 trial for Alcohol Use Disorder (AUD).
• Continue enrollment and conduct of the RESTORE Phase 2 trial for Alcohol-Associated Liver Disease (ALD).
• Actively pursue additional equity or debt financing, and monetization of existing programs through partnership arrangements or sales to third parties for long-term capital needs.
• Defend vigorously against the recently filed class action litigation.

Key Dates

Recommendation

The strong topline results from the Phase 2b IMPACT trial for pemvidutide in MASH, particularly the high MASH resolution rates and favorable safety profile, are highly encouraging and position Altimmune as a significant player in a large and underserved market. While the fibrosis improvement was not statistically significant in the primary analysis, the AI-based analysis and non-invasive test results still suggest anti-fibrotic activity. The company's improved cash position, secured through a new term loan and successful ATM offerings, provides a runway for continued development. Despite the ongoing accumulated deficit and new class action litigation, the compelling clinical data for pemvidutide, combined with its expansion into AUD and ALD, suggests substantial upside potential for investors willing to accept the inherent risks of a clinical-stage biopharmaceutical company. The market for GLP-1/glucagon agonists is robust, and pemvidutide's differentiated profile could lead to significant value creation.

Keywords

Altimmune, pemvidutide, MASH, NASH, GLP-1, glucagon, dual receptor agonist, biopharmaceutical, clinical trial, Phase 2b, liver disease, cardiometabolic, obesity, AUD, ALD, Alcohol Use Disorder, Alcohol-Associated Liver Disease, biotech, drug development, SEC filing, 10-Q